ATE481985T1
(de)
|
2002-07-03 |
2010-10-15 |
Ono Pharmaceutical Co |
Immunpotenzierende zusammensetzungen
|
SI2439273T1
(sl)
|
2005-05-09 |
2019-05-31 |
Ono Pharmaceutical Co., Ltd. |
Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
|
EP1954311A4
(en)
*
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
UA109108C2
(uk)
|
2008-12-09 |
2015-07-27 |
Дженентек, Інк. |
Антитіло до pd-l1 та його застосування для посилення функції t-клітин
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
EP2533806B1
(en)
|
2010-02-10 |
2019-09-04 |
Mayo Foundation for Medical Education and Research |
Methods and materials for treating cancer
|
CN105648056A
(zh)
|
2010-05-14 |
2016-06-08 |
综合医院公司 |
鉴定肿瘤特异性新抗原的组合物和方法
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
WO2012149540A1
(en)
|
2011-04-28 |
2012-11-01 |
The Broad Institute Inc |
Inhibitors of histone deacetylase
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
CN107722122B
(zh)
|
2011-09-23 |
2022-05-27 |
昂考梅德药品有限公司 |
Vegf/dll4结合剂及其应用
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
US9517258B2
(en)
|
2012-03-15 |
2016-12-13 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
JP6448533B2
(ja)
*
|
2012-05-15 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
CA2880117C
(en)
|
2012-07-27 |
2021-04-06 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
JP6449160B2
(ja)
|
2012-10-01 |
2019-01-09 |
アダプティブ バイオテクノロジーズ コーポレイション |
適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
US9328116B2
(en)
|
2012-12-07 |
2016-05-03 |
Chemocentryx, Inc. |
Diazole lactams
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
KR102158924B1
(ko)
|
2013-03-15 |
2020-09-22 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
AR095363A1
(es)
*
|
2013-03-15 |
2015-10-14 |
Genentech Inc |
Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
BR112015025347A2
(pt)
|
2013-04-09 |
2017-07-18 |
Boston Biomedical Inc |
2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
|
SG11201508528TA
(en)
|
2013-05-02 |
2015-11-27 |
Anaptysbio Inc |
Antibodies directed against programmed death-1 (pd-1)
|
JP2016520643A
(ja)
|
2013-06-03 |
2016-07-14 |
ノバルティス アーゲー |
抗pd−l1抗体とmek阻害薬および/またはbraf阻害薬の組み合わせ物
|
GB2517896B
(en)
|
2013-06-11 |
2015-07-08 |
Cilag Gmbh Int |
Injection device
|
GB2515032A
(en)
|
2013-06-11 |
2014-12-17 |
Cilag Gmbh Int |
Guide for an injection device
|
GB2515038A
(en)
|
2013-06-11 |
2014-12-17 |
Cilag Gmbh Int |
Injection device
|
GB2515039B
(en)
|
2013-06-11 |
2015-05-27 |
Cilag Gmbh Int |
Injection Device
|
EP4036118A1
(en)
|
2013-08-01 |
2022-08-03 |
Five Prime Therapeutics, Inc. |
Afucosylated anti-fgfr2iiib antibodies
|
KR20240056664A
(ko)
*
|
2013-09-11 |
2024-04-30 |
메디뮨 리미티드 |
종양 치료용 항-b7-h1 항체
|
PL3702373T3
(pl)
*
|
2013-09-13 |
2022-12-05 |
Beigene Switzerland Gmbh |
Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
|
HUE062317T2
(hu)
|
2013-09-20 |
2023-10-28 |
Bristol Myers Squibb Co |
Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015051245A1
(en)
*
|
2013-10-04 |
2015-04-09 |
Pin Pharma, Inc. |
Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
|
US10202454B2
(en)
*
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
JP6535337B2
(ja)
*
|
2013-11-05 |
2019-06-26 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び/またはアゴニストにより癌を治療するための組み合わせ療法
|
JP2016540042A
(ja)
*
|
2013-11-05 |
2016-12-22 |
コグネート バイオサービシズ, インコーポレイテッド |
がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
|
US20150164047A1
(en)
*
|
2013-11-07 |
2015-06-18 |
Urban Pet Haus, LLC |
Edible cat toy
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
WO2015088930A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
|
US20160303231A1
(en)
*
|
2013-12-11 |
2016-10-20 |
Robert Iannone |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
SG10201804945WA
(en)
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
WO2015094996A2
(en)
*
|
2013-12-17 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
|
BR112016013896A2
(pt)
*
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
|
EP3084001A4
(en)
*
|
2013-12-17 |
2017-07-12 |
Merck Sharp & Dohme Corp. |
Gene signature biomarkers of tumor response to pd-1 antagonists
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
WO2015095811A2
(en)
*
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
GB201322725D0
(en)
*
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
KR102395498B1
(ko)
*
|
2014-01-06 |
2022-05-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
|
WO2015103989A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for immunotherapy
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CN106659716B
(zh)
|
2014-01-24 |
2021-03-12 |
人工智能治疗公司 |
阿吡莫德组合物及其使用方法
|
AU2015210886A1
(en)
*
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3107538B1
(en)
*
|
2014-02-18 |
2020-05-27 |
Health Research, Inc. |
Combination therapy for hepatocellular carcinoma
|
US10308721B2
(en)
*
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3572430A3
(en)
|
2014-03-05 |
2020-02-12 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
WO2015143223A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
EP3119426A4
(en)
*
|
2014-03-19 |
2018-02-28 |
Mayo Foundation for Medical Education and Research |
Methods and materials for treating cancer
|
CN103897036B
(zh)
*
|
2014-03-24 |
2016-02-24 |
郑州大学 |
一种pd-1蛋白胞外段亲和肽l8及其应用
|
WO2015157623A1
(en)
|
2014-04-11 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Immune gene signatures in urothelial carcinoma (uc)
|
AU2015260962B2
(en)
*
|
2014-05-13 |
2020-06-11 |
Medimmune Limited |
Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
|
EP3760229A3
(en)
|
2014-05-15 |
2021-04-07 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
EP3149042B1
(en)
|
2014-05-29 |
2019-08-28 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
JP6652557B2
(ja)
|
2014-05-30 |
2020-02-26 |
ヴェンタナ メディカル システムズ, インク. |
Pd−l1について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
|
ES2755395T3
(es)
|
2014-06-06 |
2020-04-22 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
|
US20170106067A1
(en)
*
|
2014-06-12 |
2017-04-20 |
The Johns Hopkins University |
Combinatorial immunotherapy for pancreatic cancer treatment
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
KR102130600B1
(ko)
*
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
ES2903029T3
(es)
*
|
2014-07-03 |
2022-03-30 |
Univ Yale |
La inhibición de DICKKOPF2 (DKK2) suprime la formación de tumores
|
WO2016006241A1
(ja)
*
|
2014-07-09 |
2016-01-14 |
日本全薬工業株式会社 |
抗イヌpd-1抗体又は抗イヌpd-l1抗体
|
EP3166976B1
(en)
|
2014-07-09 |
2022-02-23 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
RU2715038C2
(ru)
*
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
RS65136B1
(sr)
|
2014-07-17 |
2024-02-29 |
Novo Nordisk As |
Mutageza usmerena na lokaciju trem-1 antitela za smanjenje viskoziteta
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
US9980956B2
(en)
*
|
2014-08-01 |
2018-05-29 |
3M Innovative Properties Company |
Methods and therapeutic combinations for treating tumors
|
EP3177649B1
(en)
|
2014-08-05 |
2024-02-28 |
Apollomics Inc. |
Anti-pd-l1 antibodies
|
CA2957387A1
(en)
|
2014-08-07 |
2016-02-11 |
Hyogo College Of Medicine |
Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
ES2890669T3
(es)
|
2014-09-09 |
2022-01-21 |
Janssen Biotech Inc |
Terapias de combinación con anticuerpos anti-CD38
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
EP3197918A1
(en)
|
2014-09-25 |
2017-08-02 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using an anti-fucosyl-gm1 antibody
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
AU2015339306B2
(en)
*
|
2014-10-29 |
2021-07-22 |
Bristol-Myers Squibb Company |
Combination therapy for cancer
|
WO2016070051A2
(en)
*
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
CN107249638B
(zh)
|
2014-11-07 |
2021-05-14 |
人工智能治疗公司 |
阿匹莫德用于治疗肾癌
|
CA2966660A1
(en)
|
2014-11-13 |
2016-05-19 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
US10100129B2
(en)
|
2014-11-21 |
2018-10-16 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
PL3221346T3
(pl)
|
2014-11-21 |
2021-03-08 |
Bristol-Myers Squibb Company |
Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
|
WO2016086036A2
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
JP6622814B2
(ja)
*
|
2014-11-25 |
2019-12-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
イメージングのための新規pd−l1結合ポリペプチド
|
AU2015358462A1
(en)
|
2014-12-04 |
2017-07-27 |
Bristol-Myers Squibb Company |
Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
|
KR102597989B1
(ko)
|
2014-12-04 |
2023-11-02 |
얀센 바이오테크 인코포레이티드 |
급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
|
US20180133313A1
(en)
*
|
2014-12-16 |
2018-05-17 |
Bristol-Myers Squibb Company |
Use of immune checkpoint inhibitors in central nervous systems neoplasms
|
JP6649953B2
(ja)
*
|
2014-12-19 |
2020-02-19 |
スサヴィオン バイオサイエンシーズ インコーポレイテッド |
免疫療法による治療および組成物
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
WO2016106160A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Enumeral Biomedical Holdings, Inc. |
Methods for screening therapeutic compounds
|
AU2015369683B2
(en)
|
2014-12-23 |
2020-12-10 |
Bristol-Myers Squibb Company |
Antibodies to TIGIT
|
ES2897707T3
(es)
|
2014-12-24 |
2022-03-02 |
Neximmune Inc |
Composiciones de nanopartículas y procedimientos para la inmunoterapia
|
EP3240908A2
(en)
*
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
GB201500374D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
WO2016118832A1
(en)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Cancer immunotherapy
|
WO2016124558A1
(en)
|
2015-02-03 |
2016-08-11 |
Ventana Medical Systems, Inc. |
Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
EP3256161A1
(en)
*
|
2015-02-09 |
2017-12-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
WO2016138182A1
(en)
*
|
2015-02-24 |
2016-09-01 |
Nodality, Inc. |
Methods and compositions for immunomodulation
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
CN107405401B
(zh)
*
|
2015-02-26 |
2022-02-01 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
KR20240064733A
(ko)
*
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
WO2016145427A1
(en)
|
2015-03-12 |
2016-09-15 |
Health Research, Inc. |
COMBINATION OF β-ADRENERGIC RECEPTOR ANTAGONISTS AND CHECK POINT INHIBITORS FOR IMPROVED EFFICACY AGAINST CANCER
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
WO2016149387A1
(en)
*
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer
|
LT3274370T
(lt)
|
2015-03-23 |
2020-02-10 |
Bayer Pharma Aktiengesellschaft |
Antikūnai prieš ceacam6 ir jų panaudojimas
|
WO2016162368A1
(en)
*
|
2015-04-07 |
2016-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Non-invasive imaging of tumor pd-l1 expression
|
EP3280439A1
(en)
*
|
2015-04-07 |
2018-02-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Anti-pd-l1 immunotoxin for use in therapy
|
EP3280738A4
(en)
|
2015-04-08 |
2019-01-02 |
Nantomics, LLC |
Cancer neoepitopes
|
LT3283527T
(lt)
|
2015-04-13 |
2021-03-25 |
Five Prime Therapeutics, Inc. |
Kompleksinė terapija vėžio gydymui
|
US20180312844A1
(en)
*
|
2015-04-13 |
2018-11-01 |
The Board of Regents of the UIniversity of Texas System |
Treatment for cancer metastasis
|
CN113577264A
(zh)
*
|
2015-04-17 |
2021-11-02 |
百时美施贵宝公司 |
包含抗pd-1抗体和另外的抗体的组合的组合物
|
CN108513593A
(zh)
|
2015-04-23 |
2018-09-07 |
南托米克斯有限责任公司 |
癌症新表位
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
EP3288980B1
(en)
|
2015-04-28 |
2021-03-10 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
WO2016177682A1
(en)
|
2015-05-06 |
2016-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
US10766965B2
(en)
|
2015-05-20 |
2020-09-08 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
CN104931690A
(zh)
*
|
2015-05-22 |
2015-09-23 |
华中科技大学同济医学院附属协和医院 |
一种pd-1抗体检测试剂盒及其应用
|
US20180155429A1
(en)
*
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
SG10202008304TA
(en)
|
2015-05-29 |
2020-10-29 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
MX2017014736A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
CA2987115C
(en)
|
2015-06-01 |
2024-02-20 |
Peter C. Brooks |
Enhancing the therapeutic activity of an immune checkpoint inhibitor
|
TW201717935A
(zh)
*
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
US10995140B2
(en)
|
2015-06-05 |
2021-05-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
CN106243225B
(zh)
*
|
2015-06-11 |
2021-01-19 |
智翔(上海)医药科技有限公司 |
新型抗-pd-l1抗体
|
EA201792522A1
(ru)
|
2015-06-12 |
2018-05-31 |
Бристол-Майерс Сквибб Компани |
Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
|
EP3310810A1
(en)
|
2015-06-16 |
2018-04-25 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
CR20170587A
(es)
|
2015-06-22 |
2018-04-03 |
Janssen Biotech Inc |
Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
|
BR112017027990A2
(pt)
*
|
2015-06-24 |
2018-08-28 |
Janssen Biotech, Inc. |
modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
|
US20170044265A1
(en)
*
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
CA2990107A1
(en)
*
|
2015-06-24 |
2016-12-29 |
Immodulon Therapeutics Limited |
A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
EA202092187A1
(ru)
|
2015-06-29 |
2021-08-31 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Способы лечения эпителиоидно-клеточных опухолей
|
US9861621B2
(en)
|
2015-06-29 |
2018-01-09 |
Biomed Valley Discoveries, Inc. |
LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
KR20180019229A
(ko)
*
|
2015-06-29 |
2018-02-23 |
아브락시스 바이오사이언스, 엘엘씨 |
나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법
|
US11179385B2
(en)
*
|
2015-06-30 |
2021-11-23 |
The Trustees Of The University Of Pennsylvania |
Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
|
MX2018000621A
(es)
*
|
2015-07-13 |
2018-05-11 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
|
US10007766B2
(en)
|
2015-07-13 |
2018-06-26 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
|
US10544224B2
(en)
|
2015-07-14 |
2020-01-28 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor
|
NZ739503A
(en)
|
2015-07-16 |
2023-06-30 |
Bioxcel Therapeutics Inc |
A novel approach for treatment of cancer using immunomodulation
|
MX2018001227A
(es)
|
2015-07-30 |
2018-03-26 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas.
|
EP3328896A4
(en)
|
2015-07-31 |
2019-08-07 |
University of Florida Research Foundation, Inc. |
HEMATOPOIETIC STEM CELLS IN COMBINATORY THERAPY WITH IMMUNCHECKPOINT INHIBITORS AGAINST CANCER
|
CN106397592A
(zh)
*
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
KR102434314B1
(ko)
|
2015-09-01 |
2022-08-19 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
WO2017040960A1
(en)
*
|
2015-09-04 |
2017-03-09 |
The Brigham And Women's Hospital, Inc. |
Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
|
DK3349731T3
(da)
*
|
2015-09-16 |
2024-01-08 |
Univ Texas |
Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft
|
JP6967003B2
(ja)
|
2015-09-23 |
2021-11-17 |
メレオ バイオファーマ 5 インコーポレイテッド |
がんの処置のための方法および組成物
|
US20210284734A1
(en)
*
|
2015-10-02 |
2021-09-16 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
CA3003251A1
(en)
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
PE20181300A1
(es)
|
2015-11-02 |
2018-08-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
|
WO2017079150A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
US10894830B2
(en)
|
2015-11-03 |
2021-01-19 |
Janssen Biotech, Inc. |
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
|
TWI705972B
(zh)
*
|
2015-11-04 |
2020-10-01 |
臺北榮民總醫院 |
惡性病變的組合治療
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
CN109608544B
(zh)
|
2015-11-17 |
2022-09-16 |
苏州盛迪亚生物医药有限公司 |
Pd-l1抗体、其抗原结合片段及其医药用途
|
WO2017087870A1
(en)
|
2015-11-18 |
2017-05-26 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
|
SG11201803817PA
(en)
|
2015-11-19 |
2018-06-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
AU2016355268B2
(en)
*
|
2015-11-20 |
2021-08-19 |
Senhwa Biosciences, Inc. |
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
WO2017085307A1
(en)
|
2015-11-22 |
2017-05-26 |
Ventana Medical Systems, Inc. |
Methods of identifying immune cells in pd-l1 positive tumor tissue
|
CA3004794A1
(en)
*
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
US20190113423A1
(en)
*
|
2015-12-02 |
2019-04-18 |
Clearlight Diagnostics, LLC |
Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
|
EP3322713B1
(en)
|
2015-12-03 |
2021-01-20 |
GlaxoSmithKline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017106061A1
(en)
|
2015-12-14 |
2017-06-22 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
JP6762363B2
(ja)
*
|
2015-12-18 |
2020-09-30 |
アンスティテュ・ギュスターヴ・ルシー |
Pd−1/pdl−1を標的とする薬物に対する応答を評価する方法
|
EP3394093B1
(en)
|
2015-12-23 |
2022-01-26 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
WO2017123911A1
(en)
*
|
2016-01-15 |
2017-07-20 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
CN105717298A
(zh)
*
|
2016-01-29 |
2016-06-29 |
浙江数问生物技术有限公司 |
Pd-l1免疫组化试剂盒
|
US11710539B2
(en)
|
2016-02-01 |
2023-07-25 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
|
WO2017134306A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Cd8 binding agents
|
WO2017139755A1
(en)
*
|
2016-02-12 |
2017-08-17 |
Rekoske Brian T |
Cancer therapy
|
WO2017143115A2
(en)
*
|
2016-02-18 |
2017-08-24 |
Maine Medical Center Research Institute |
Enhancing the therapeutic activity of an immune checkpoint inhibitor
|
BR112018067368A2
(pt)
|
2016-03-04 |
2019-01-15 |
Bristol-Myers Squibb Company |
terapia de combinação com anticorpos anti-cd73
|
CN107922503B
(zh)
|
2016-03-04 |
2018-08-28 |
四川科伦博泰生物医药股份有限公司 |
一种pdl-1抗体、其药物组合物及其用途
|
WO2017156152A1
(en)
*
|
2016-03-08 |
2017-09-14 |
Bioxcel Corporation |
Immunomodulation therapies for cancer
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
CN111363041B
(zh)
*
|
2016-03-23 |
2022-02-22 |
苏州创胜医药集团有限公司 |
新型抗-pd-l1抗体
|
KR20180129873A
(ko)
*
|
2016-03-31 |
2018-12-05 |
아시이리스 파머수티클 테크놀로지스 코퍼레이션 리미티드 |
암 치료에서 니트록솔린 및 그의 유사체의 화학요법 및 면역요법과의 조합적 사용
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
CA3019391A1
(en)
|
2016-04-07 |
2017-10-12 |
Chemocentryx, Inc. |
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|
MX2018012333A
(es)
|
2016-04-07 |
2019-03-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas.
|
WO2017176565A1
(en)
|
2016-04-07 |
2017-10-12 |
Eli Lilly And Company |
Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
|
RU2018137389A
(ru)
|
2016-04-07 |
2020-05-12 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Гетероциклические амиды, полезные в качестве модуляторов
|
EP3443013A4
(en)
*
|
2016-04-14 |
2019-11-20 |
Creatv Microtech, Inc. |
METHOD FOR USE OF PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
|
WO2017181034A1
(en)
|
2016-04-14 |
2017-10-19 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
US11963980B2
(en)
|
2016-04-25 |
2024-04-23 |
Musc Foundation For Research Development |
Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
CA3024917A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
JP7246930B2
(ja)
|
2016-05-18 |
2023-03-28 |
モデルナティエックス インコーポレイテッド |
インターロイキン-12(il12)をコードするポリヌクレオチドおよびその使用
|
IL292302B2
(en)
|
2016-05-20 |
2023-10-01 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating factors in cancer immunotherapy
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
WO2017205801A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Takeda Pharmaceutical Company Limited |
Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
|
EP3463486A1
(en)
|
2016-06-01 |
2019-04-10 |
Bristol-Myers Squibb Company |
Pet imaging with pd-l1 binding polypeptides
|
AU2017273726B2
(en)
|
2016-06-01 |
2023-10-19 |
Epizyme, Inc. |
Use of EZH2 inhibitors for treating cancer
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
EP4248990A3
(en)
*
|
2016-06-02 |
2024-01-03 |
Bristol-Myers Squibb Company |
Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
|
WO2017210473A1
(en)
|
2016-06-02 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
KR102515509B1
(ko)
|
2016-06-03 |
2023-03-28 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
EP3463454A1
(en)
|
2016-06-03 |
2019-04-10 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
US20200325226A1
(en)
*
|
2016-06-03 |
2020-10-15 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treating a tumor
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
WO2017214182A1
(en)
*
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
US20190298705A1
(en)
|
2016-06-08 |
2019-10-03 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
AU2017279027A1
(en)
|
2016-06-08 |
2018-12-20 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
CN107488229B
(zh)
*
|
2016-06-13 |
2020-11-17 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
CN109475603B
(zh)
|
2016-06-20 |
2023-06-13 |
科马布有限公司 |
抗pd-l1抗体
|
TW201803598A
(zh)
|
2016-06-30 |
2018-02-01 |
南特細胞公司 |
Nant癌症疫苗
|
EP3481393B1
(en)
|
2016-07-05 |
2021-04-14 |
Beigene, Ltd. |
Combination of a pd-1 antagonist and a raf inhibitor for treating cancer
|
MY200602A
(en)
|
2016-07-14 |
2024-01-04 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
CN109789135A
(zh)
|
2016-07-20 |
2019-05-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为perk抑制剂的异喹啉衍生物
|
EP3494140A1
(en)
*
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
JP7198752B2
(ja)
|
2016-08-09 |
2023-01-04 |
カイマブ・リミテッド |
抗icos抗体
|
KR101966496B1
(ko)
|
2016-08-18 |
2019-04-08 |
울산대학교 산학협력단 |
기계식 잠금 방식을 적용한 usb 보안잠금장치 및 그 usb 보안잠금장치를 이용한 usb 기계식 보안잠금방법
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
MX2019002474A
(es)
|
2016-09-01 |
2019-09-18 |
Mayo Found Medical Education & Res |
Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
|
JP2019535001A
(ja)
*
|
2016-09-06 |
2019-12-05 |
インセルディーエックス・インコーポレーテッド |
細胞あたりのpd−l1発現量を検出する方法及びその使用
|
US11726089B2
(en)
|
2016-09-06 |
2023-08-15 |
Incelldx, Inc. |
Methods of assaying neoplastic and neoplasia-related cells and uses thereof
|
US20190218294A1
(en)
*
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
CN110191720A
(zh)
|
2016-09-09 |
2019-08-30 |
Tg治疗有限公司 |
用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
|
CN109890420B
(zh)
*
|
2016-09-13 |
2024-04-09 |
北卡罗来纳州立大学 |
用于递送治疗剂的血小板组合物和方法
|
CA3037230A1
(en)
*
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
EP3522923A1
(en)
|
2016-10-06 |
2019-08-14 |
Pfizer Inc |
Dosing regimen of avelumab for the treatment of cancer
|
EP3526323B1
(en)
|
2016-10-14 |
2023-03-29 |
Precision Biosciences, Inc. |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
EP3383915A4
(en)
*
|
2016-10-15 |
2019-07-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
PD-1 ANTIBODY
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
KR20240019398A
(ko)
|
2016-10-28 |
2024-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
BR112019008859A2
(pt)
|
2016-11-01 |
2019-07-09 |
Anaptysbio Inc |
anticorpos direcionados contra a morte programada 1 (pd-1)
|
CA3039992A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
AU2017355446A1
(en)
|
2016-11-03 |
2019-05-02 |
Bristol-Myers Squibb Company |
Activatable anti-CTLA-4 antibodies and uses thereof
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
AU2017355512A1
(en)
*
|
2016-11-04 |
2019-05-23 |
Aximmune, Inc. |
Beta-alethine, immune modulators, and uses thereof
|
WO2018089688A1
(en)
|
2016-11-09 |
2018-05-17 |
Jinjun Shi |
Restoration of tumor suppression using mrna-based delivery system
|
BR112019009771A2
(pt)
|
2016-11-14 |
2019-09-17 |
Dinona |
ligação de anticorpos especificamente à cd66c e utilização dos mesmos
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
JP2020500878A
(ja)
*
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
併用療法
|
HRP20231579T1
(hr)
|
2016-12-07 |
2024-03-15 |
Agenus Inc. |
Anti-ctla-4 antitijela i postupci njihove upotrebe
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd8a結合フィブロネクチンiii型ドメイン
|
US10597438B2
(en)
|
2016-12-14 |
2020-03-24 |
Janssen Biotech, Inc. |
PD-L1 binding fibronectin type III domains
|
CN106519034B
(zh)
*
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
EP3566054A4
(en)
|
2017-01-05 |
2020-12-09 |
Biodesix, Inc. |
PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY
|
CN110382545A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗pd-1抗体治疗癌症的方法
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
US11325976B2
(en)
|
2017-02-16 |
2022-05-10 |
Ying Zhang |
Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
US20200062735A1
(en)
|
2017-02-27 |
2020-02-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
WO2018162944A1
(en)
|
2017-03-04 |
2018-09-13 |
Shenzhen Runshin Bioscience |
Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
|
EP3592769B1
(en)
|
2017-03-09 |
2024-05-08 |
Genmab A/S |
Antibodies against pd-l1
|
US20200031944A1
(en)
|
2017-03-31 |
2020-01-30 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
AU2018243754A1
(en)
|
2017-03-31 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
CN110809582B
(zh)
*
|
2017-05-01 |
2023-12-22 |
儿童医疗中心有限公司 |
涉及抗pd1抗体试剂的方法以及组合物
|
CA3058952A1
(en)
*
|
2017-05-02 |
2018-11-08 |
Dana-Farber Cancer Institute, Inc. |
Il-23r antagonists to reprogram intratumoral t regulatory cells into effector cells
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
BR112019023898A2
(pt)
|
2017-05-16 |
2020-06-09 |
Five Prime Therapeutics Inc |
método para tratamento de câncer gástrico, uso de um anticorpo e composição
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
AU2018270111B2
(en)
|
2017-05-18 |
2022-07-14 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
EP3630833A1
(en)
|
2017-05-25 |
2020-04-08 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
EP4245375A3
(en)
|
2017-05-30 |
2023-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
KR20200010501A
(ko)
|
2017-05-30 |
2020-01-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 양성 종양의 치료
|
CA3065304A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
BR112019025188A2
(pt)
*
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
EP3630840A1
(en)
|
2017-06-01 |
2020-04-08 |
Bristol-Myers Squibb Company |
Methods of treating a tumor using an anti-pd-1 antibody
|
JP2020522687A
(ja)
*
|
2017-06-02 |
2020-07-30 |
エピザイム,インコーポレイティド |
癌を処置するためのezh2阻害剤の使用
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
CN110869049A
(zh)
|
2017-06-09 |
2020-03-06 |
葛兰素史克知识产权开发有限公司 |
组合疗法
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
JP2020525411A
(ja)
|
2017-06-26 |
2020-08-27 |
ベイジーン リミテッド |
肝細胞癌のための免疫療法
|
KR20230142819A
(ko)
|
2017-06-27 |
2023-10-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
BR112020000086A2
(pt)
|
2017-07-03 |
2020-07-07 |
Glaxosmithkline Intellectual Property Development Limited |
derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物
|
EP3652534B1
(en)
*
|
2017-07-13 |
2024-03-27 |
Institut Gustave Roussy |
A radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and survival of cancer patients treated with anti-pd-1/pd-l1
|
US11344543B2
(en)
|
2017-07-14 |
2022-05-31 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
KR20200033930A
(ko)
|
2017-07-28 |
2020-03-30 |
브리스톨-마이어스 스큅 컴퍼니 |
체크포인트 억제제에 대한 예측성 말초 혈액 바이오마커
|
BR112020001944A2
(pt)
|
2017-08-04 |
2020-08-04 |
Genmab A/S |
agente de ligação, ácido nucleico, vetor de expressão, célula, composição, métodos para tratamento de uma doença e para produção de um anticorpo biespecífico, uso de um agente de ligação, e, anticorpo anti-idiotípico.
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
MX2020001875A
(es)
|
2017-08-18 |
2020-07-29 |
Tragara Pharmaceuticals Inc |
Forma polimorfica de tg02.
|
CN111094982A
(zh)
*
|
2017-08-28 |
2020-05-01 |
百时美施贵宝公司 |
用于治疗和诊断癌症的tim-3拮抗剂
|
KR20200045520A
(ko)
|
2017-09-07 |
2020-05-04 |
오거스타 유니버시티 리서치 인스티튜트, 인크. |
프로그래밍된 세포사 단백질 1에 대한 항체
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
US11421034B2
(en)
|
2017-09-13 |
2022-08-23 |
Five Prime Therapeutics, Inc. |
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
|
KR20200110300A
(ko)
|
2017-09-25 |
2020-09-23 |
케모센트릭스, 인크. |
케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
EP3692033A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
US10927180B2
(en)
|
2017-10-13 |
2021-02-23 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍処置法
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
AU2018359527A1
(en)
|
2017-10-31 |
2020-05-07 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
DE102017125780B3
(de)
*
|
2017-11-05 |
2018-12-13 |
Dimo Dietrich |
Verfahren zur Bestimmung des Ansprechens einer malignen Erkrankung auf eine Immuntherapie
|
JP2021502344A
(ja)
|
2017-11-06 |
2021-01-28 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
WO2019097082A1
(en)
*
|
2017-11-20 |
2019-05-23 |
Julius-Maximilians-Universität Würzburg |
Cd19cart cells eliminate myeloma cells that express very low levels of cd19
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
CN107973854B
(zh)
*
|
2017-12-11 |
2021-05-04 |
苏州银河生物医药有限公司 |
Pdl1单克隆抗体及其应用
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CA3084582A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
KR20200103761A
(ko)
|
2017-12-27 |
2020-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
CN109970857B
(zh)
*
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CA3082036A1
(en)
|
2017-12-29 |
2019-07-04 |
Ap Biosciences, Inc. |
Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
|
US20200385478A1
(en)
*
|
2018-01-05 |
2020-12-10 |
Biograph 55, Inc. |
Compositions and methods for cancer immunotherapy
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
WO2019136368A2
(en)
|
2018-01-08 |
2019-07-11 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
WO2019137397A1
(zh)
|
2018-01-10 |
2019-07-18 |
江苏恒瑞医药股份有限公司 |
Pd-l1抗体、其抗原结合片段及医药用途
|
JP2021510697A
(ja)
|
2018-01-12 |
2021-04-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
がん処置のための坑il−8抗体及び坑pd−1抗体を用いる組合せ治療
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
US20210177781A9
(en)
|
2018-01-12 |
2021-06-17 |
KDAc Therapeutics, Inc. |
Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
|
CN111868091A
(zh)
|
2018-01-16 |
2020-10-30 |
百时美施贵宝公司 |
用抗tim3抗体治疗癌症的方法
|
EA202091751A1
(ru)
|
2018-01-22 |
2020-11-06 |
Бристол-Маерс Сквибб Компани |
Композиции и способы лечения рака
|
EP3743061A1
(en)
|
2018-01-22 |
2020-12-02 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
US11814623B2
(en)
|
2018-01-30 |
2023-11-14 |
University Of Massachusetts |
Methods of treating a wound using epigenetic regulation
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
EP3749295A4
(en)
|
2018-02-05 |
2022-04-27 |
Orionis Biosciences, Inc. |
FIBROBLAST BINDING AGENTS AND USES THEREOF
|
EP4317972A3
(en)
|
2018-02-06 |
2024-03-13 |
The General Hospital Corporation |
Repeat rna as biomarkers of tumor immune response
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
AU2019227294B2
(en)
|
2018-02-15 |
2023-06-15 |
Senhwa Biosciences, Inc. |
Quinolone analogs and their salts, compositions, and method for their use
|
WO2019169162A1
(en)
*
|
2018-03-01 |
2019-09-06 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for treating cancer
|
KR102043468B1
(ko)
|
2018-03-14 |
2019-11-11 |
경북대학교 산학협력단 |
엡스타인 바 바이러스 연관 위암의 재발 가능성 예측을 위한 정보제공 방법
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
CA3092635A1
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
CN111971304A
(zh)
|
2018-03-21 |
2020-11-20 |
戊瑞治疗有限公司 |
在酸性pH结合至VISTA的抗体
|
JP7328983B2
(ja)
|
2018-03-22 |
2023-08-17 |
サーフィス オンコロジー インコーポレイテッド |
抗il-27抗体及びその使用
|
US11242393B2
(en)
|
2018-03-23 |
2022-02-08 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
CA3094318A1
(en)
|
2018-03-30 |
2019-10-03 |
Merus N.V. |
Multivalent antibody
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
KR20200140867A
(ko)
|
2018-04-06 |
2020-12-16 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
MX2020010606A
(es)
|
2018-04-09 |
2021-01-15 |
Eisai R&D Man Co Ltd |
Compuestos de pladienolida y su uso.
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
JOP20200244A1
(ar)
|
2018-04-12 |
2020-09-29 |
Eisai R&D Man Co Ltd |
مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
|
KR20200142542A
(ko)
|
2018-04-12 |
2020-12-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
|
US10907161B2
(en)
|
2018-04-19 |
2021-02-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
US20210267964A1
(en)
|
2018-04-25 |
2021-09-02 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
AU2019266205A1
(en)
|
2018-05-07 |
2020-10-22 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
|
JP7460608B2
(ja)
|
2018-05-07 |
2024-04-02 |
ジェンマブ エー/エス |
抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
IL278740B2
(en)
|
2018-06-01 |
2024-01-01 |
Eisai R&D Man Co Ltd |
Methods for using splicing modulators
|
WO2019232449A1
(en)
|
2018-06-01 |
2019-12-05 |
Eisai R&D Management Co., Ltd. |
Splicing modulator antibody-drug conjugates and methods of use
|
WO2019234576A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
EP3820895A4
(en)
*
|
2018-07-09 |
2022-04-27 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
EFFICIENTLY EXPRESSED EGFR AND PD-L1 BINDER PROTEINS
|
EP3820843A1
(en)
|
2018-07-09 |
2021-05-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds
|
MX2021000009A
(es)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
AU2019306628A1
(en)
|
2018-07-20 |
2021-02-11 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
US20210238287A1
(en)
*
|
2018-07-26 |
2021-08-05 |
Bristol-Myers Squibb Company |
LAG-3 Combination Therapy for the Treatment of Cancer
|
US20210292851A1
(en)
*
|
2018-07-27 |
2021-09-23 |
Roche Sequencing Solutions, Inc. |
Method of monitoring effectiveness of immunotherapy of cancer patients
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CA3109778A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
JP7364663B2
(ja)
|
2018-08-16 |
2023-10-18 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター
|
KR20210045430A
(ko)
|
2018-08-16 |
2021-04-26 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
CA3111401A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
KR20210086623A
(ko)
|
2018-09-25 |
2021-07-08 |
하푼 테라퓨틱스, 인크. |
Ddl3 결합 단백질 및 사용 방법
|
JP2022512642A
(ja)
|
2018-10-09 |
2022-02-07 |
ブリストル-マイヤーズ スクイブ カンパニー |
がんを治療するための抗MerTK抗体
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
CN113286611A
(zh)
|
2018-10-19 |
2021-08-20 |
百时美施贵宝公司 |
用于黑色素瘤的组合疗法
|
WO2020086479A1
(en)
|
2018-10-22 |
2020-04-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
US20210380693A1
(en)
|
2018-10-23 |
2021-12-09 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
TW202034958A
(zh)
|
2018-10-30 |
2020-10-01 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
WO2020089432A1
(en)
*
|
2018-11-02 |
2020-05-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method of pancreatic cancer
|
CA3118789A1
(en)
|
2018-11-06 |
2020-05-14 |
Genmab A/S |
Antibody formulation
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
SG11202105078XA
(en)
|
2018-11-14 |
2021-06-29 |
Bayer Ag |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
TW202033555A
(zh)
|
2018-11-16 |
2020-09-16 |
美商必治妥美雅史谷比公司 |
抗nkg2a抗體及其用途
|
CA3119341A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
JP2022507495A
(ja)
|
2018-11-16 |
2022-01-18 |
アーキュール・インコーポレイテッド |
癌治療のための医薬の組合せ
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
CN113613724A
(zh)
|
2018-11-30 |
2021-11-05 |
葛兰素史克知识产权开发有限公司 |
可用于hiv疗法的化合物
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
KR20210102274A
(ko)
|
2018-12-13 |
2021-08-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
헤르복시디엔 항체-약물 접합체 및 사용 방법
|
CA3124773A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene |
M2-defective poxvirus
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Nlrp3モジュレーター
|
ES2930151T3
(es)
|
2019-01-14 |
2022-12-07 |
Innate Tumor Immunity Inc |
Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
|
JP7373571B2
(ja)
|
2019-01-14 |
2023-11-02 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がん治療に用いるためのnlrp3モジュレーターとしての置換キナゾリン
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
EP3922647A4
(en)
|
2019-02-03 |
2023-05-24 |
Jiangsu Hengrui Medicine Co., Ltd. |
ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
|
EP3921443A1
(en)
*
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
AU2020248002A1
(en)
|
2019-03-26 |
2021-10-21 |
The Regents Of The University Of Michigan |
Small molecule degraders of STAT3
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
KR20210146349A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
WO2020205467A1
(en)
|
2019-03-29 |
2020-10-08 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
WO2020208612A1
(en)
|
2019-04-12 |
2020-10-15 |
Vascular Biogenics Ltd. |
Methods of anti-tumor therapy
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
WO2020236850A1
(en)
*
|
2019-05-20 |
2020-11-26 |
Immunovalent Therapeutics Inc. |
Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes
|
EP3972982A1
(en)
|
2019-05-20 |
2022-03-30 |
Massachusetts Institute of Technology |
Boronic ester prodrugs and uses thereof
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
EP3980205A4
(en)
*
|
2019-06-07 |
2023-08-23 |
The Trustees of Princeton University |
PROXIMITY-BASED MARKING SYSTEMS AND ASSOCIATED APPLICATIONS
|
WO2020252336A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
AU2020291464A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
CN110684844B
(zh)
*
|
2019-06-27 |
2023-01-24 |
中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) |
RBPJL基因的p.P476S突变作为PD-1抗体用药指导标志物中的应用
|
US20220356255A1
(en)
|
2019-07-15 |
2022-11-10 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
PE20220750A1
(es)
|
2019-07-16 |
2022-05-10 |
Univ Michigan Regents |
Imidazopirimidinas como inhibidores de eed y uso de estas
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US11851490B2
(en)
|
2019-08-15 |
2023-12-26 |
Northwestern University |
Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
JP2022545735A
(ja)
|
2019-08-27 |
2022-10-28 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
セレブロンe3リガーゼ阻害剤
|
CN113795510A
(zh)
*
|
2019-08-29 |
2021-12-14 |
荣昌生物制药(烟台)股份有限公司 |
抗pd-l1抗体及其应用
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
EP4013512B1
(en)
|
2019-09-18 |
2024-02-14 |
LamKap Bio alpha AG |
Bispecific antibodies against ceacam5 and cd3
|
CA3155010A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The Universtiy Of Michigan |
Spirocyclic androgen receptor protein degraders
|
JP2022548292A
(ja)
|
2019-09-19 |
2022-11-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
酸性pHでVISTAと結合する抗体
|
KR20220066334A
(ko)
|
2019-09-22 |
2022-05-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
|
JP7122354B2
(ja)
|
2019-09-24 |
2022-08-19 |
財團法人工業技術研究院 |
抗tigit抗体および使用方法
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
US20220339249A1
(en)
|
2019-09-25 |
2022-10-27 |
Bristol-Myers Squibb Company |
Composite biomarker for cancer therapy
|
CA3151928A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Nikolai Kley |
Pd-l1 targeted chimeric proteins and uses thereof
|
CN114729049A
(zh)
|
2019-09-27 |
2022-07-08 |
葛兰素史密斯克莱知识产权发展有限公司 |
抗原结合蛋白
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
US11628222B2
(en)
|
2019-10-14 |
2023-04-18 |
Aro Biotherapeutics Company |
CD71 binding fibronectin type III domains
|
WO2021074683A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
Bispecific anti-pd-l1 and anti-fcrn polypeptides
|
CN115279905A
(zh)
|
2019-10-23 |
2022-11-01 |
里珍纳龙药品有限公司 |
合成rig-i样受体激动剂
|
KR102325962B1
(ko)
*
|
2019-10-28 |
2021-11-12 |
경북대학교 산학협력단 |
칼슘 채널 차단제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
|
JP2022554356A
(ja)
|
2019-11-04 |
2022-12-28 |
シージェン インコーポレイテッド |
抗cd30抗体薬物コンジュゲート及びhiv感染の処置のためのその使用
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
JP2022553851A
(ja)
|
2019-11-08 |
2022-12-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
黒色腫の処置のためのlag-3アンタゴニスト
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
EP4076529A1
(en)
|
2019-12-19 |
2022-10-26 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
JP7480307B2
(ja)
|
2020-01-29 |
2024-05-09 |
メルス ナムローゼ フェンノートシャップ |
免疫細胞関与効果を調節するための手段および方法
|
AU2021213969A1
(en)
|
2020-01-30 |
2022-09-01 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
EP4110407A1
(en)
|
2020-02-28 |
2023-01-04 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
EP4114398A1
(en)
|
2020-03-06 |
2023-01-11 |
Celgene Quanticel Research, Inc. |
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
|
BR112022016720A2
(pt)
|
2020-03-06 |
2022-11-16 |
Ona Therapeutics S L |
Anticorpos anti-cd36 e seu uso para tratamento de câncer
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
JP2023519254A
(ja)
|
2020-03-23 |
2023-05-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
がんを処置するための抗ccr8抗体
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
AU2021256925A1
(en)
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
WO2021222544A1
(en)
|
2020-05-01 |
2021-11-04 |
Ngm Biopharmaceuticals, Inc. |
Ilt-binding agents and methods of use thereof
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
EP4157319A1
(en)
|
2020-05-28 |
2023-04-05 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
JP2023532768A
(ja)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
Hpv陽性癌の治療用rna
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
TW202221031A
(zh)
|
2020-07-30 |
2022-06-01 |
英商阿法克塔生命科學有限公司 |
血清半衰期延長之pd-l1抑制多肽
|
EP4196502A1
(en)
|
2020-08-13 |
2023-06-21 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
WO2022047189A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
EP4225770A1
(en)
|
2020-10-05 |
2023-08-16 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
EP4236960A1
(en)
|
2020-10-28 |
2023-09-06 |
Ikena Oncology, Inc. |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
IL302836A
(en)
|
2020-11-17 |
2023-07-01 |
Seagen Inc |
Methods for treating cancer with a combination of tocatinib and an anti-PD-1/anti-PD-L1 antibody
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
KR20230121772A
(ko)
|
2020-12-18 |
2023-08-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135457A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
广东菲鹏制药股份有限公司 |
一种抗pd-l1抗体及其应用
|
EP4267172A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
MX2023007734A
(es)
|
2020-12-28 |
2023-08-21 |
Bristol Myers Squibb Co |
Composiciones de anticuerpos y metodos de uso de las mismas.
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
CA3204392A1
(en)
|
2021-01-08 |
2022-07-14 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-gm1 antibody
|
EP4282413A1
(en)
|
2021-01-21 |
2023-11-29 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Composition and method for treating tumors
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
WO2022208353A1
(en)
|
2021-03-31 |
2022-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
CN113087801B
(zh)
*
|
2021-04-07 |
2022-07-05 |
深圳市核子基因科技有限公司 |
一种用核酸和抗体联合检测肺癌的试剂盒
|
US20220389089A1
(en)
|
2021-05-07 |
2022-12-08 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
US20230034659A1
(en)
*
|
2021-06-17 |
2023-02-02 |
Sparx Bioscience Limited |
Anti-pdl1 antibodies and uses thereof
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
WO2023031366A1
(en)
|
2021-09-02 |
2023-03-09 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Anti-cecam6 antibodies with reduced side-effects
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
IL311771A
(en)
|
2021-10-06 |
2024-05-01 |
BioNTech SE |
Multispecific binding agents against PD-L1 and CD137 in combination
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
AU2022377637A1
(en)
|
2021-10-28 |
2024-05-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
CA3236735A1
(en)
|
2021-10-29 |
2023-05-04 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023091951A1
(en)
*
|
2021-11-16 |
2023-05-25 |
The Regents Of The University Of California |
Methods to enhance therapeutic efficacy in melanoma via modulation of tumor cell surface pd-l1/l2
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023192946A1
(en)
*
|
2022-03-31 |
2023-10-05 |
Ventana Medical Systems, Inc. |
Methods and systems for predicting response to pd-1 axis directed therapeutics in colorectal tumors with deficient mismatch repair
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
WO2023230473A1
(en)
|
2022-05-24 |
2023-11-30 |
Bristol-Myers Squibb Company |
Antibodies that bind to human ccr8
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023242351A1
(en)
|
2022-06-16 |
2023-12-21 |
Lamkap Bio Beta Ag |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
WO2024015803A2
(en)
|
2022-07-11 |
2024-01-18 |
Autonomous Therapeutics, Inc. |
Encrypted rna and methods of its use
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|